VYNE Therapeutics (VYNE) Profit After Tax (2016 - 2026)
VYNE Therapeutics (VYNE) posted Profit After Tax of -$3.6 million for Q1 2026, up 37.71% on a QoQ basis from -$5.8 million in Q2 2025, and up 58.46% year-over-year from -$2.3 million in Q1 2025.
VYNE Therapeutics (VYNE) Profit After Tax (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Profit After Tax history runs 11 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- Quarterly Profit After Tax rose 58.46% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.0 million (up 28.78% YoY) and the FY2025 annual result came in at -$26.5 million, up 33.53% from the prior year.
- Profit After Tax was -$3.6 million for Q1 2026 at VYNE Therapeutics, up from -$5.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $4.7 million in Q1 2022 and bottomed at -$12.1 million in Q3 2024.
- A 5-year average of -$7.1 million and a median of -$7.8 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax jumped 142.94% — and 2023, when it plunged 220.17%.
- VYNE Therapeutics' Profit After Tax stood at -$7.8 million in 2022, then advanced by 20.6% to -$6.2 million in 2023, then tumbled by 95.5% to -$12.0 million in 2024, then soared by 52.23% to -$5.8 million in 2025, then surged by 37.71% to -$3.6 million in 2026.
- Business Quant data shows VYNE's Profit After Tax at -$3.6 million in Q1 2026, -$5.8 million in Q2 2025, and -$8.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.59 Mn |
| Jun 30, 2025 | -5.76 Mn |
| Mar 31, 2025 | -8.63 Mn |
| Dec 31, 2024 | -12.05 Mn |
| Sep 30, 2024 | -12.07 Mn |
| Jun 30, 2024 | -9.41 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Dec 31, 2023 | -6.16 Mn |
| Sep 30, 2023 | -6.58 Mn |
| Jun 30, 2023 | -10.06 Mn |
| Mar 31, 2023 | -5.61 Mn |
| Dec 31, 2022 | -7.76 Mn |
| Sep 30, 2022 | -9.26 Mn |
| Jun 30, 2022 | -8.24 Mn |
| Mar 31, 2022 | 4.67 Mn |
| Dec 31, 2021 | 17.55 Mn |
| Sep 30, 2021 | -21.29 Mn |
| Jun 30, 2021 | -19.92 Mn |
| Mar 31, 2021 | -10.88 Mn |
| Dec 31, 2020 | -23.18 Mn |